Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: Potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment

Satoshi Tanida, Tsutomu Mizoshita, Keiji Ozeki, Hironobu Tsukamoto, Takeshi Kamiya, Hiromi Kataoka, Daitoku Sakamuro, Takashi Joh

Research output: Contribution to journalReview article

47 Citations (Scopus)

Abstract

Cisplatin is the most important and efficacious chemotherapeutic agent for the treatment of advanced gastric cancer. Cisplatin forms inter- and intrastrand crosslinked DNA adducts and its cytotoxicity is mediated by propagation of DNA damage recognition signals to downstream pathways involving ATR, p53, p73, and mitogen-activated protein kinases, ultimately resulting in apoptosis. Cisplatin resistance arises through a multifactorial mechanism involving reduced drug uptake, increased drug inactivation, increased DNA damage repair, and inhibition of transmission of DNA damage recognition signals to the apoptotic pathway. In addition, a new mechanism has recently been revealed, in which the oncoprotein c-Myc suppresses bridging integrator 1 (BIN1), thereby releasing poly(ADP-ribose)polymerase 1, which results in increased DNA repair activity and allows cancer cells to acquire cisplatin resistance. The present paper focuses on the molecular mechanisms of cisplatin-induced apoptosis and of cisplatin resistance, in particular on the involvement of BIN1 in the maintenance of cisplatin sensitivity.

Original languageEnglish (US)
Article number862879
JournalInternational Journal of Surgical Oncology
Volume2012
DOIs
StatePublished - Sep 18 2012
Externally publishedYes

Fingerprint

Cisplatin
Stomach Neoplasms
Apoptosis
DNA Damage
DNA Repair
DNA Adducts
Oncogene Proteins
Mitogen-Activated Protein Kinases
Pharmaceutical Preparations
Maintenance
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity : Potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. / Tanida, Satoshi; Mizoshita, Tsutomu; Ozeki, Keiji; Tsukamoto, Hironobu; Kamiya, Takeshi; Kataoka, Hiromi; Sakamuro, Daitoku; Joh, Takashi.

In: International Journal of Surgical Oncology, Vol. 2012, 862879, 18.09.2012.

Research output: Contribution to journalReview article

@article{147c2db9fb19401d81a3e411b5728d26,
title = "Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: Potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment",
abstract = "Cisplatin is the most important and efficacious chemotherapeutic agent for the treatment of advanced gastric cancer. Cisplatin forms inter- and intrastrand crosslinked DNA adducts and its cytotoxicity is mediated by propagation of DNA damage recognition signals to downstream pathways involving ATR, p53, p73, and mitogen-activated protein kinases, ultimately resulting in apoptosis. Cisplatin resistance arises through a multifactorial mechanism involving reduced drug uptake, increased drug inactivation, increased DNA damage repair, and inhibition of transmission of DNA damage recognition signals to the apoptotic pathway. In addition, a new mechanism has recently been revealed, in which the oncoprotein c-Myc suppresses bridging integrator 1 (BIN1), thereby releasing poly(ADP-ribose)polymerase 1, which results in increased DNA repair activity and allows cancer cells to acquire cisplatin resistance. The present paper focuses on the molecular mechanisms of cisplatin-induced apoptosis and of cisplatin resistance, in particular on the involvement of BIN1 in the maintenance of cisplatin sensitivity.",
author = "Satoshi Tanida and Tsutomu Mizoshita and Keiji Ozeki and Hironobu Tsukamoto and Takeshi Kamiya and Hiromi Kataoka and Daitoku Sakamuro and Takashi Joh",
year = "2012",
month = "9",
day = "18",
doi = "10.1155/2012/862879",
language = "English (US)",
volume = "2012",
journal = "International Journal of Surgical Oncology",
issn = "2090-1402",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity

T2 - Potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment

AU - Tanida, Satoshi

AU - Mizoshita, Tsutomu

AU - Ozeki, Keiji

AU - Tsukamoto, Hironobu

AU - Kamiya, Takeshi

AU - Kataoka, Hiromi

AU - Sakamuro, Daitoku

AU - Joh, Takashi

PY - 2012/9/18

Y1 - 2012/9/18

N2 - Cisplatin is the most important and efficacious chemotherapeutic agent for the treatment of advanced gastric cancer. Cisplatin forms inter- and intrastrand crosslinked DNA adducts and its cytotoxicity is mediated by propagation of DNA damage recognition signals to downstream pathways involving ATR, p53, p73, and mitogen-activated protein kinases, ultimately resulting in apoptosis. Cisplatin resistance arises through a multifactorial mechanism involving reduced drug uptake, increased drug inactivation, increased DNA damage repair, and inhibition of transmission of DNA damage recognition signals to the apoptotic pathway. In addition, a new mechanism has recently been revealed, in which the oncoprotein c-Myc suppresses bridging integrator 1 (BIN1), thereby releasing poly(ADP-ribose)polymerase 1, which results in increased DNA repair activity and allows cancer cells to acquire cisplatin resistance. The present paper focuses on the molecular mechanisms of cisplatin-induced apoptosis and of cisplatin resistance, in particular on the involvement of BIN1 in the maintenance of cisplatin sensitivity.

AB - Cisplatin is the most important and efficacious chemotherapeutic agent for the treatment of advanced gastric cancer. Cisplatin forms inter- and intrastrand crosslinked DNA adducts and its cytotoxicity is mediated by propagation of DNA damage recognition signals to downstream pathways involving ATR, p53, p73, and mitogen-activated protein kinases, ultimately resulting in apoptosis. Cisplatin resistance arises through a multifactorial mechanism involving reduced drug uptake, increased drug inactivation, increased DNA damage repair, and inhibition of transmission of DNA damage recognition signals to the apoptotic pathway. In addition, a new mechanism has recently been revealed, in which the oncoprotein c-Myc suppresses bridging integrator 1 (BIN1), thereby releasing poly(ADP-ribose)polymerase 1, which results in increased DNA repair activity and allows cancer cells to acquire cisplatin resistance. The present paper focuses on the molecular mechanisms of cisplatin-induced apoptosis and of cisplatin resistance, in particular on the involvement of BIN1 in the maintenance of cisplatin sensitivity.

UR - http://www.scopus.com/inward/record.url?scp=84866153536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866153536&partnerID=8YFLogxK

U2 - 10.1155/2012/862879

DO - 10.1155/2012/862879

M3 - Review article

C2 - 22778941

AN - SCOPUS:84866153536

VL - 2012

JO - International Journal of Surgical Oncology

JF - International Journal of Surgical Oncology

SN - 2090-1402

M1 - 862879

ER -